OBJECTIVES: To evaluate the efficacy of combined finasteride and flutamide therapy in men
with advanced prostate cancer by determining (1) the short-term tolerability of finasteride …

To identify and describe the frequency and severity of hepatotoxicity in patients who
received flutamide therapy for prostate cancer, 22 patients were treated with the combination …

PURPOSE: To examine the frequency and severity of toxicity associated with flutamide
inpatients treated with total androgen suppression before and during pelvic radiation …

Purpose: We investigated the tolerability, safety and antitumor effects of a novel
intraprostatic depot formulation of antiandrogen 2-hydroxyflutamide (in NanoZolid®) in men …

Background: The present study was designed to ascertain retrospectively the validity of
ursodeoxycholic acid (UDCA) in the treatment of prostate cancer in terms of prophylactic …

PURPOSE To determine the therapeutic effects of bicalutamide 200 mg in patients with
prostate cancers of different hormone sensitivities. METHODS Patients with progressive …

The effect of short term administration of flutamide on the hypothalamic-pituitary-gonadal
axis was studied in six patients with advanced prostate cancer (C2 stage). Flutamide …

OBJECTIVE To determine the prostate‐specific antigen (PSA) response and time to PSA or
radiographic progression in men with prostate cancer refractory to bicalutamide and/or …

Background Flutamide withdrawal has been reported to benefit patients with hormone‐
refractory prostate cancer. Several studies have also demonstrated that a combination of …

Background/Aim: There are few reports that verify the relationship between the therapeutic
effects of flutamide and novel androgen receptor-targeted agents. We aimed to evaluate the …